Scilex Holding (SCLX) Net Income towards Common Stockholders (2020 - 2026)

Scilex Holding (SCLX) posted quarterly Net Income towards Common Stockholders of -$43.3 million for Q1 2026, down 65.91% year-over-year from -$126.9 million in Q1 2025, and down 30.68% on a QoQ basis from -$33.1 million in Q4 2025.

Scilex Holding (SCLX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Scilex Holding (SCLX) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$43.3 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 65.91% year-over-year to -$43.3 million; the TTM figure through Mar 2026 stood at -$419.7 million (down 403.18% YoY), while the FY2025 annual figure was -$402.5 million, down 392.63% from the prior year.
  • Net Income towards Common Stockholders came in at -$43.3 million for Q1 2026 at Scilex Holding, down from -$33.1 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $21.5 million in Q3 2022, with the low at -$257.2 million in Q3 2025.
  • Average Net Income towards Common Stockholders over 5 years is -$42.2 million, with a median of -$26.1 million recorded in 2025.
  • The largest YoY upside for Net Income towards Common Stockholders was 7736.6% in 2022 against a maximum downside of 10688.09% in 2022.
  • Year by year, Net Income towards Common Stockholders stood at -$17.9 million in 2022, then decreased by 19.66% to -$21.4 million in 2023, then gained by 28.25% to -$15.4 million in 2024, then slumped by 115.64% to -$33.1 million in 2025, then sank by 30.68% to -$43.3 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$43.3 million, -$33.1 million, and -$257.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 7.40 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 5.24 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 697.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 47.33 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -4.21 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 2.02 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -13.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - 1.65
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn -43.27 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -43.27 Mn
Dec 31, 2025 -33.11 Mn
Sep 30, 2025 -257.23 Mn
Jun 30, 2025 -86.06 Mn
Mar 31, 2025 -26.08 Mn
Dec 31, 2024 -15.36 Mn
Sep 30, 2024 -4.39 Mn
Jun 30, 2024 -37.58 Mn
Mar 31, 2024 -24.38 Mn
Dec 31, 2023 -21.40 Mn
Sep 30, 2023 -88.17 Mn
Jun 30, 2023 -26.65 Mn
Mar 31, 2023 -30.75 Mn
Dec 31, 2022 -17.88 Mn
Sep 30, 2022 21.50 Mn
Jun 30, 2022 -17.84 Mn
Mar 31, 2022 -9.14 Mn
Dec 31, 2021 -35.26 Mn
Sep 30, 2021 -281,552.00
Jun 30, 2021 -165,349.00